State rules for drug discounts
Novartis Pharmaceuticals v. Fitch
In brief
- Where it stands
- Petition Pending
Awaiting an order on the petition
- What it’s about
- Novartis challenges Mississippi laws that it says impose additional requirements on drugmakers participating in the federal 340B drug-discount program, arguing that they conflict with federal law.
- What's at stake
- Whether Mississippi may impose the challenged requirements on drugmakers participating in 340B remains unresolved.
Summary: written with AI from the case record.
What it's about
The Supreme Court distributed Novartis’s petition for a conference but has not agreed to hear the case.
The dispute concerns how Mississippi's requirements for 340B participants fit with the federal program.
Question presented
Whether state laws imposing different and more expansive program terms on drug manufacturers who participate in the federal 340B Program violate the Supremacy Clause?
What happens next
The petition was distributed for the Court's Nov. 6, 2026, conference, where the next question is whether the Court will hear it. No oral argument or decision date is set.
Documents
Docket activity
Case data updated: title
New analysis added
AI analysis generated: Case Briefing
Case data updated: summary, question_presented, generation_metadata
Case data updated: question_presented, extraction_metadata
Show 2 moreShow fewer
Brief added: Petition
Court Order added: Lower Court Orders/Opinions
Sources
Primary materials plus reporting. Best-effort analysis: this explainer relies on a mix of primary materials and trusted secondary sources. Official filings and opinions remain authoritative.